TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01756729

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovoTTF-100A
Description: Multiple four-week courses of continuous NovoTTF-100A treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100A
Description: Multiple four-week courses of continuous NovoTTF-100A treatment.
Study: NCT05659446

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopy management of low output colonic fistula or leak after anterior resection for rectal cancer
Description: Patients involved in endoscopic group were firstly subjected for Interventional Radiology to drain any intra-peritoneal collection present in preoperative radiology then were subjected either to Clips application (OTSC, OVASCO Endoscopy AG. Tubingen, Germany) or Endo-suturing (Overstitch, Apollo Endo-Surgery , TX, United states) to close the low output fistula or leak after anterior resection for rectal cancer. The endoscopy was done under sedation, not general anesthesia after colonic preparation (chemical \& mechanical preparation) firstly, to detect size of fistula . Clips were used in cases with fistula's size less than 10 mm, while Endo-suturing devices were used in cases with fistula's size more than 10mm till 15mm.
Study: NCT00002520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT04126382

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubate-Surfactant-Extubate(INSURE)
Description: Infants are given an endotracheal intubation, with manual lung inflation in order to keep the oxygen supply，and the surfactant(kelisu,China Resources Shuanghe Pharmaceutical) was slowly instilled into the airway through the tracheal tube, and the tracheal tube was removed for non-invasive NCPAP(nasal continuous positive airway pressure)-assisted breathing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: less invasive surfactant administration(LISA)
Description: Infants are spontaneously breathing with nasal CPAP(continuous positive airway pressure) support without manual lung inflation and surfactant(kelisu,China Resources Shuanghe Pharmaceutical) is administered through vocal cords via a smaller catheter.
Study: NCT04222751

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ankle Splint
Description: Ankle splint will be slightly modified from the commercial form to include a pneumatic air cell secured under the forefoot below the splint's padded lining. This replaces the foam wedge provided by the manufacturer, allowing a gradual adjustment of the forefoot/toe region.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Splint
Description: Ankle splint will be slightly modified from the commercial form to include a pneumatic air cell secured under the forefoot below the splint's padded lining. This replaces the foam wedge provided by the manufacturer, allowing a gradual adjustment of the forefoot/toe region.
Study: NCT00728221

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng
Description: Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: whole root in capsules (3g)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (Panax ginseng)
Description: Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total ginsenoside fraction in capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cornstarch
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (Panax Ginseng)
Description: Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total polysaccharide fraction (panaxans) in capsules
Study: NCT00764556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Intravenous insulin (actrapid) Subcutaneous insulin (aspart, glargine, detemir)
Study: NCT04013594

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate group
Description: Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery.
Study: NCT00626743

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SK3530 100mg, Placebo, Amlodipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK3530 100mg, Placebo, Amlodipine
Study: NCT03074929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Novel risk communication
Description: The investigators will develop novel risk communication messages to communicate the risks of childhood obesity to parents of children with obesity. The investigators will consider several novel approaches around message content and framing, but primarily, we propose using microsimulation models to forecast a child's long-term health risks, based on his age, race, gender, BMI, and family history of CVD.
Study: NCT03891550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa
Description: sofosbuvir (SOF) 400 mg/Velpatasvir(VEL) 100 mg fixed-dosage combination once-daily for 12 weeks for all HCV genotype patients with and without hepatic decompensation
Study: NCT03907332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visits
Description: An experimental design, a cluster randomized controlled trial (RCT) will be used. A total of 20 clusters will be randomized with block randomization of electoral areas with a) resident staff midwives and b) resident Community Health Nurse midwifes. All women residing in an electoral area will receive the same intervention for practicality and to prevent contamination.
Study: NCT02015169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: lapatinib 1250mg qd daily up to 8 cycles (3 weeks \* 8 cycles = 24 weeks)
Study: NCT02808390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0507-34-Levo 80 mg
Description: GED-0507-34-Levo 80 mg BID for 8 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0507-34-Levo 160 mg
Description: GED-0507-34-Levo 160 mg BID for 8 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo BID for 8 Weeks
Study: NCT01558063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Single dose of 0.1, 0.2, 0.3, 0.4 or 0.5 mg/kg of ketamine given intravenously over 40 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Single dose of 0.1, 0.2, 0.3, 0.4 or 0.5 mg/kg of ketamine given intravenously over 40 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Single dose of 0.1, 0.2, 0.3, 0.4 or 0.5 mg/kg of ketamine given intravenously over 40 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Single dose of 0.1, 0.2, 0.3, 0.4 or 0.5 mg/kg of ketamine given intravenously over 40 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Single dose of 0.1, 0.2, 0.3, 0.4 or 0.5 mg/kg of ketamine given intravenously over 40 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Single infusion of saline given intravenously over 40 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: 90-minute scan during the 40-minute infusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: 90-minute scan during the 40-minute infusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: 90-minute scan during the 40-minute infusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: 90-minute scan during the 40-minute infusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: 90-minute scan during the 40-minute infusion.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: 90-minute scan during the 40-minute infusion.
Study: NCT00504946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone, colecalciferol, lactose
Description: Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone + 1000j colecalciferol + 0.3mg lactose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~0.3mg lactose
Study: NCT03221894

Intervention type: DIETARY_SUPPLEMENT
Intervention: GRAPE granules
Description: GRAPE granules was mainly consisted of herbal medicines: Ren Shen (Ginseng, 10g/d), Di Huang (Rehmannia glutinosa, 30g/d), Shi Cangpu (Acorus tatarinowii, 10g/d), Yuan Zhi (Polygala tenuifolia, 10g/d), Yin Yanghuo (Epimedium brevicornu, 10g/d), Shan Zhuyu (Cornus officinalis, 10g/d), Rou Congrong (Cistanche deserticola, 10g/d), Yu Jin (Curcuma aromatica, 10g/d), Dan Shen (Salvia miltiorrhiza, 10g/d), Tian Ma (Angelica sinensis, 10g/d), Tian ma (Gastrodia elata, 10g/d), and Huang Lian (Berberine, 10g/d), which were supplied by Beijing Tcmages Pharmaceutical Co., LTD, Each bag of granules with 150ml warm water melt was taken orally twice a day.
Study: NCT00508391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimized interventricular delay biventricular pacing
Description: Lumax HF-T with optimized interventricular delay biventricular pacing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimized interventricular delay biventricular pacing
Description: Lumax HF-T with optimized interventricular delay biventricular pacing
Study: NCT05983289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653
Description: HSK7653 tablets in six doses beginning at 5 mg and rising to 150 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tables in six doses beginning at 5 mg and rising to 150 mg
Study: NCT03737162

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent implantation of subclavian artery
Description: Stent implantation of subclavian artery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent implantation of subclavian artery
Description: Stent implantation of subclavian artery
Study: NCT04438031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation Intervention Prenatal 1.0 (intervention discontinued, modified to 2.0. Data will not be used)
Description: This program recruits mothers in OB/GYN (prenatal) offices, provides up to three Navigation visits (using prenatal navigation version 1.0), establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Intervention
Description: Brief information will be provided about pregnancy prenatally and child development at 12, 24, and 36 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation Intervention Prenatal 2.0
Description: This program recruits mothers in OB/GYN offices. Mothers are offered visits from a Navigator prenatally and postnatally (12-, 24-, and 36-months). During visits, the Navigator works with the mother to identify family needs, establishes connections between the family and community providers, and follows up one month later to confirm these referrals. Navigators assess and support family needs across 13 factors: caregiver health, infant health, healthcare plans, childcare plans, parent-child relationship, management of infant crying/behavior, household safety/material supports, family/community violence, history of parenting difficulties, parent well-being, substance use, parent emotional support, and other needs not related to first 12 factors. Navigation 2.0 is a revision of 1.0 in which adjustments to the protocol were made to improve guidance for Community Navigators and aid their assessments of family needs.
Study: NCT00504946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: Allergen immunotherapy (build-up phase)premedication with montelukast sodium. Children 6-14 years received 5 mg of montelukast and children \> 14 years old received 10mg oral tablet once daily at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: Allergen immunotherapy (build-up phase)premedication with 0,3mg lactose once daily at bedtime
Study: NCT03557840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temocillin
Description: Drug dosing and blood sampling as per the protocol
Study: NCT01680198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracalcitol
Description: Patients in the experimental arm received 2 micrograms Paricalcitol capsules daily, for 12 weeks. This dose was adjusted based on clinical laboratory parameters and the maximum dose was 2 micrograms daily.
Study: NCT00330187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Description: Bupropion SR, with goal dose 300 mg/day, for 6 weeks of active treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion SR
Description: Bupropion SR, with goal dose 300 mg/day, for 6 weeks of active treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Contingency Management provided at twice-weekly visits during the 6-week active treatment. Escalating schedule, with resets, reinforcing smoking abstinence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: Contingency Management provided at twice-weekly visits during the 6-week active treatment. Escalating schedule, with resets, reinforcing smoking abstinence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, matched in appearance to Bupropion SR, for 6 weeks of treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, matched in appearance to Bupropion SR, for 6 weeks of treatment
Study: NCT01196559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine and Gemcitabine
Description: Gmcitabine 1000㎎/㎡ mix in normal saline 100ml iv for 30min andVinorelbine 25㎎/㎡ mix in normal saline 50 ml iv for 5-10min on D1 and 8 every 21 days cycle
Study: NCT01568203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 579
Description: 3 dose levels of single oral dose administration of AMG 579 in healthy subjects (Part A), and 5 dose levels of single oral dose administration of AMG 579 in patients with schizophrenia or schizoaffective disorder (Part B)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo control for AMG 579 at each dose level
Study: NCT00760981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: The single cohort for this study will receive 2 dose levels of imatinib, 200 mg orally daily followed by 400 mg orally daily.
Study: NCT01974609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narcotic
Description: Hydrocodone 5mg + acetaminophen 325 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-narcotic
Description: ibuprofen 600mg + acetaminophen 325 mg
Study: NCT03221218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced screening-informed follow up letter
Description: Family Physicians will be sent a letter that includes their screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines.
Study: NCT01311700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable (i.v.) metoprolol tartrate (up to 15 mg).
Description: Patients are randomized to active intervention (early metoprolol initiation strategy) or no treatment (delayed metoprolol initiation strategy).~Patients randomized to early metoprolol initiation strategy receive up to three 5mg i.v. dosages (2 minutes apart) before reperfusion.~Patients randomized to delayed metoprolol initiation strategy receive no active treatment before reperfusion.~Patients in both groups receive oral metoprolol tartrate treatment (25-100mg/12h), starting 12-24 hr post-reperfusion.
Study: NCT02685709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide capsules
Study: NCT03543085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GiMer Medical MN 1000 External Stimulator
Description: Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (\>200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
Study: NCT01682850

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Pulmonary Rehabilitation
Description: Participants in this group will under go 10 sessions of mindfulness based pulmonary rehabilitation prior to surgery. Each session is about 2 hours long and consists of upper /lower extremity training, breathing exercises, and education.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Study: NCT03295214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen given for pain relief

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen given for pain relief
Study: NCT03336502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole 18 mg/mL IV solution; posaconazole 40 mg/mL oral suspension
Study: NCT02935309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Pre-surgery Lenvatinib, days 1 - 5. Dose Escalation Levels: 1.) 10 mg by mouth (PO) daily (QD); 2.) 14 mg PO QD; 3.) 20 mg PO QD; 4.) 24 PO QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Pre-surgery Capecitabine, 850 mg/m\^2, twice a day (BID) on days 1-5 for 5½ -6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Radiation Therapy (XRT)
Description: Pre-surgery RT: Participants will receive 6 weeks of radiation therapy. The radiation sessions will be daily, Monday through Friday, except for holidays.
Study: NCT03869255

Intervention type: PROCEDURE
Intervention: Nasal swab
Description: In hospitalized patiens, a nasal swab will be performed within the first 48 hours and on the 7th day. In community patient, only one swab will be performed

Intervention type: PROCEDURE
Intervention: Nasal swab
Description: In hospitalized patiens, a nasal swab will be performed within the first 48 hours and on the 7th day. In community patient, only one swab will be performed
Study: NCT00216970

Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: Alteration in nutritional support
Description: The subject is randomized into one of two groups - One receives TPN that does not have arginine, proline or glutamate. The other will receive TPN with extra glutamine. The subject takes part in 3 tracer studies while in the hospital. For each tracer study, the subject will receive a different randomly assigned diet. Blood and air are sampled and the patient receives a stable isotope after which the tests are repeated.

Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: Alteration in nutritional support
Description: The subject is randomized into one of two groups - One receives TPN that does not have arginine, proline or glutamate. The other will receive TPN with extra glutamine. The subject takes part in 3 tracer studies while in the hospital. For each tracer study, the subject will receive a different randomly assigned diet. Blood and air are sampled and the patient receives a stable isotope after which the tests are repeated.
Study: NCT02952183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAMS I
Description: After general anesthesia, pressure sensor of PAMS I is placed into bladder, vagina and rectum. Then pressure change is monitored during performing pelvic autonomic nerve dissection.~Both PAMS I and IOM will be used for monitoring.
Study: NCT02094144

Intervention type: OTHER
Group type: OTHER
Intervention: Brisk walking program
Description: The intervention consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program

Intervention type: OTHER
Group type: OTHER
Intervention: physical activity habit
Description: The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
Study: NCT03719157

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral ESP Block
Description: USG guided ESP block will perform unilateral with Bupivacaine and Lidocain mixture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral OSTAP Block
Description: USG guided OSTAP block will perform unilateral with Bupivacaine and Lidocain mixture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection of Local Anesthetic to Trocar Insertion
Description: Bupivacaine infiltration will be performed at the end of the surgical procedure to trocar insertion sites.
Study: NCT01680198

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02386189

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Care Coordination Training
Description: Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.